Experimental infusion aims to fix bone marrow failure in rare telomere disease

NCT ID NCT04211714

Ongoing Disease control Sponsor: Elixirgen Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a single infusion of EXG34217 in 12 people aged 12 and older who have bone marrow failure due to telomere biology disorders. The main goal is to check safety and tolerability, while also looking at changes in telomere length and blood cell counts. Because it is a small Phase I/II study, it is too soon to know if the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EXG34217 (a biological therapy given as a single infusion)
What this could lead to: If it works, this could point toward a treatment that improves blood counts and lengthens telomeres in patients with telomere biology disorders.
What could go wrong: This is a very early, small Phase I/II trial with only 12 participants, focused on safety. It may not show clear benefit, and risks like immune reactions or lack of effectiveness are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE MARROW FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bone Marrow Failure Disorders bone marrow failure syndrome telomere syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE MARROW FAILURE TELOMERE SHORTENING

Contacts and locations

Locations

Cincinnati Children's Hospital

Cincinnati, Ohio, 45229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.